Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) is now available.
On December 9, 2025, Structure Therapeutics, Inc. entered into an underwriting agreement to issue and sell American Depositary Shares (ADSs) and pre-funded warrants in a public offering. The offering is expected to generate approximately $650 million in gross proceeds, with the closing anticipated on December 11, 2025, subject to customary conditions. This move is part of the company’s strategy to raise capital, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GPCR) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.
Spark’s Take on GPCR Stock
According to Spark, TipRanks’ AI Analyst, GPCR is a Underperform.
Structure Therapeutics, Inc.’s overall score is largely impacted by its financial performance, reflecting significant financial sustainability risks due to zero revenues and increasing losses, despite strong cash positions. The technical analysis provides a mixed view with some short-term momentum but longer-term concerns. The valuation remains challenging with a negative P/E ratio, indicating a speculative investment reliant on future success in R&D and commercialization.
To see Spark’s full report on GPCR stock, click here.
More about Structure Therapeutics, Inc. Sponsored ADR
Average Trading Volume: 1,396,684
Technical Sentiment Signal: Buy
Current Market Cap: $4.25B
Learn more about GPCR stock on TipRanks’ Stock Analysis page.